Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Decrease in Short Interest

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 774,700 shares, a decrease of 79.0% from the October 31st total of 3,690,000 shares. Based on an average daily volume of 15,910,000 shares, the short-interest ratio is presently 0.0 days. Approximately 3.5% of the shares of the stock are sold short.

Tevogen Bio Stock Up 2.2 %

TVGN opened at $1.37 on Thursday. Tevogen Bio has a 52 week low of $0.26 and a 52 week high of $21.09. The business’s fifty day simple moving average is $1.27 and its 200 day simple moving average is $0.89.

Insider Buying and Selling at Tevogen Bio

In related news, insider Neal Flomenberg sold 1,078,600 shares of the stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the sale, the insider now owns 4,254,302 shares of the company’s stock, valued at $6,891,969.24. This trade represents a 20.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 56.60% of the stock is owned by corporate insiders.

Institutional Trading of Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. purchased a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned about 0.13% of Tevogen Bio at the end of the most recent quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.